Loading...

Skip to main content

Call us on + 1 (800) 604-9114 for more information about our products

Looking for specific datasheet Manual/COA/MSDS?
Request a Manual/COA/MSDS

Interested to get a quote about our products?
Request a Quote

Testing Data

IgG2 Fc secondary antibody

Mouse Anti-Human IgG2 Fc-FITC

Reactivity
Human
Applications
ELISA, ELISA, Flow Cytometry, Functional Assay, Immunocytochemistry, Immunoblot, Western Blot
Synonyms
IgG2 Fc; Mouse Anti-Human IgG2 Fc-FITC; IgG2 Fc secondary antibody
Ordering
For Research Use Only!
Host
Mouse
Reactivity
Human
Isotype
IgG1kappa
Clone Number
31-7-4
Specificity
Human IgG2 Fc
Form/Format
Supplied in PBS/NaN3
Concentration
0.5 mg/mL (varies by lot)
Applicable Applications for IgG2 Fc secondary antibody
ELISA (EIA), Fluorescence-Linked Immunosorbent Assay (FLISA), ELISpot, Flow Cytometry (FC/FACS), Immunocytochemistry (ICC), Immunoblotting (IB), Multiplex
Application Notes
For direct immunostaining of IgG2 positive cells in flow cytometry applications, clone HP6002 is recommended
Volume
1.0 mL
Immunogen
Human IgG2 myeloma protein
Conjugate
FITC (Fluorescein)
Isotype Control
Mouse IgG1-FITC
Preparation and Storage
Store at 2-8 degree C.

Testing Data

Testing Data
References
1. Conley ME, Brown P, Bartlet MS. IgG subclass potential of surface IgM-negative and surface IgM-positive human peripheral blood B cells. Clin Immunol Immunopathol. 1987;43:211-22. (Immunogen, ICC). 2. Arnold M, Zacher T, Dechant M, Kalden JR, Doxiadis II, Spriewald BM. Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol. 2004;65:1288-96. (ELISA). 3. Bogdanos D, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology. 2005;42:458-65. (ELISA). 4. Whary MT, Sundina N, Bravo LE, Correa P, Quinones F, Caro F, et al. Intestinal helminthiasis in Colombian children promotes a Th2 response to Helicobacter pylori: possible implications for gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2005;14:1464-9. (ELISA). 5. Njoku DB, Mellerson JL, Talor MV, Kerr DR, Faraday NR, Outschoorn I, et al. Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. Clin Vaccine Immunol. 2006;13:258-65. (ELISA). 6. Bogdanos D, Pusl T, Rust C, Vergani D, Beuers U. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol. 2008;49:466-73. (ELISA, WB). 7. Arnold M, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens. 2008;72:60-6. (ELISA, Multiplex). 8. Pratt-Riccio LR, Sallenave-Sales S, de Oliveira-Ferreira J, da Silva BT, Guimares ML, Santos F, et al. Evaluation of the genetic polymorphism of Plasmodium falciparum P126 protein (SERA or SERP) and its influence on naturally acquired specific antibody responses in malaria-infected individuals living in the Brazilian Amazon. Malar J. 2008;7:144. (ELISA). 9. Xue L, Johnson R, Gorovits B. Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serum. AAPS J. 2010;12:98-106. (ELISA). 10. Pratt-Riccio LR, Bianco C Jr, Totino PR, Perce-Da-Silva Dde S, Silva LA, Riccio EK, et al. Antibodies against the Plasmodium falciparum glutamate-rich protein from naturally exposed individuals living in a Brazilian malaria-endemic area can inhibit in vitro parasite growth. Mem Inst Oswaldo Cruz. 2011;106 Suppl 1:34-43. (ELISA). 11. Geisler WM, Morrison SG, Doemland ML, Iqbal SM, Su J, Mancevski A, et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. J Infect Dis. 2012;206:1836-43. (ELISA). 12. Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcgamma receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014;66:1153-64. (ELISA). 13. Lue C, Tarkowski A, Mestecky J. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies. J Immunol. 1988;140:3793-800. (ELISPOT). 14. Bogdanos D, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y, et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun. 2004;22:353-62. (WB). 15. Jackson AM, Lucas DP, Melancon JK, Desai NM. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation. 2011;92:54-60. (FC). 16. Jackson AM, Kuperman MB, Montgomery RA. Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am J Transplant. 2012;12:1643-9. (FC). 17. Toyoda C, Suzuki Y, Tsuneyama H, Onodera T, Masuno A, Yabe R, et al. Production of human monoclonal anti-Jk3, recognising an epitope including the Jka/Jkb polymorphic site of the Kidd glycoprotein. Transfus Med. 2014;24:286-91. (FC). 18. Hönger G, Hopfer H, Arnold M, Spriewald BM, Schaub S, Amico P. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation. 2011;92:41-7. (Multiplex). 19. Lowe D, Higgins R, Zehnder D, Briggs DC. Significant IgG subclass heterogeneity in HLA-specific antibodies: Implications for pathogenicity, prognosis, and the rejection response. Hum Immunol. 2013;74:666-72. (Multiplex). 20. Arnold M, Ntokou I, Doxiadis II, Spriewald BM, Boletis JN, Iniotaki AG. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. Transpl Int. 2014;27:253-61. (Multiplex). 21. Schaub S, Hönger G, Koller MT, Liwski R, Amico P. Determinants of C1q binding in the single antigen bead assay. Transplantation. 2014;98:387-93. (Multiplex). 22. Lefaucheur C, Viglietti D, Bentlejewski C, van Huyen JD, Vernerey D, Aubert O, et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol. 2016;27:293-304. (Multiplex)

Similar Products

Product Notes

The IgG2 Fc (Catalog #AAA679324) is a Secondary Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Mouse Anti-Human IgG2 Fc-FITC reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's IgG2 Fc can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Fluorescence-Linked Immunosorbent Assay (FLISA), ELISpot, Flow Cytometry (FC/FACS), Immunocytochemistry (ICC), Immunoblotting (IB), Multiplex. For direct immunostaining of IgG2 positive cells in flow cytometry applications, clone HP6002 is recommended. Researchers should empirically determine the suitability of the IgG2 Fc for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "IgG2 Fc, Secondary Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.

Precautions

All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.

Disclaimer

Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.

Item has been added to Shopping Cart

If you are ready to order, navigate to Shopping Cart and get ready to checkout.

Looking for a specific manual?
Request a Manual

Request more Information

Please complete the form below and a representative will contact you as soon as possible.

Request a Manual

Please complete the form below and a representative will contact you as soon as possible.

Request a Quote

Please complete the form below and a representative will contact you as soon as possible.